Ondansetron in the treatment of cognitive decline in Alzheimer dementia

The authors performed a multicenter, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ondansetron (20 microg/day and 100 microg/ day) in treating cognitive decline in 185 patients with Alzheimer disease. Although ondansetron was well tolerated without any serious...

Full description

Saved in:

Bibliographic Details
Published in:	The American journal of geriatric psychiatry Vol. 10; no. 2; p. 212
Main Authors:	Dysken, Maurice, Kuskowski, Michael, Love, Susan
Format:	Journal Article
Language:	English
Published:	England 01-03-2002
Subjects:	Aged Alzheimer Disease - complications Alzheimer Disease - drug therapy Alzheimer Disease - psychology Cognition Disorders - drug therapy Cognition Disorders - etiology Double-Blind Method Female Humans Male Neuropsychological Tests Ondansetron - adverse effects Ondansetron - therapeutic use Serotonin Antagonists - adverse effects Serotonin Antagonists - therapeutic use Treatment Outcome
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The authors performed a multicenter, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ondansetron (20 microg/day and 100 microg/ day) in treating cognitive decline in 185 patients with Alzheimer disease. Although ondansetron was well tolerated without any serious drug-related side effects, the study failed to demonstrate any significant cognitive improvement.
ISSN:	1064-7481
DOI:	10.1097/00019442-200203000-00013